Upstream Bio, Inc.
UPB · XNASCIK 2022626fmd_02NR6GKTD10NEJJ8AX9FG2W2G0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 2 | 2 | 3 |
| Research and development | 32 | 63 | 137 |
| Total operating expenses | 42 | 80 | 163 |
| Operating income | (40) | (78) | (160) |
| Interest and investment income | 4 | 12 | 17 |
| Other non-operating income (expense) | 20 | 15 | 17 |
| Income tax expense | 0 | 0 | 0 |
| Net income | (21) | (63) | (143) |
| Net income to common shareholders | (38) | (76) | (143) |